EVIIVE AG develops blood-based liquid biopsy diagnostics to support the selection of immunotherapies in oncology. The company researches and builds extracellular vesicle (EV) biomarker platforms, including IMPASS and IMPACT, to profile cell-type specific EV signals and stratify patients for treatment.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Next-generation biomarker discovery platform for precise diagnostics in immuno-oncology; analysis of extracellular vesicles, treatment selection, response prediction and longitudinal monitoring.
Blood-based Diagnostics
Blood-based diagnostics from small plasma volumes with high-dimensional analysis of extracellular vesicles for non-invasive, clinically relevant insights into immune and tumor signals.
Immuno-Oncology Tests for Treatment Selection and Response Prediction
Diagnostic tests for early patient selection in immuno-oncology; prediction of therapy response, stratification of patient groups and support for treatment decisions.
Companion Diagnostics
Development of companion diagnostics for oncology immunotherapies; support for clinical decisions, patient selection and translational development.
EV Profiling
Profiling of extracellular vesicles to capture dynamic immune, tumor and metabolic interactions; analysis of EV subpopulations from blood samples.